Final analysis of the ELIXIR study: A prospective, multicenter, observational study to evaluate the efficacy and safety of atezolizumab plus bevacizumab (Atezo plus Bev) in Japanese patients with unresectable hepatocellular carcinoma (uHCC) in a real-world clinical setting

被引：0

作者：

Takehara, T. ^{[1
]}

Kato, N. ^{[2
]}

Aikata, H. ^{[3
]}

Kuzuya, T. ^{[4
]}

Hiasa, Y. ^{[5
]}

Nakamura, S. ^{[6
]}

Yamamoto, K. ^{[7
]}

Morimoto, N. ^{[8
]}

Sakamori, R. ^{[9
]}

Kawamura, Y. ^{[10
]}

Tsuchiya, K. ^{[11
]}

Ueshima, K. ^{[12
]}

Hiraoka, A. ^{[13
]}

Nakano, M. ^{[14
]}

Kokudo, N. ^{[15
]}

Furuse, J. ^{[16
]}

Moriguchi, M. ^{[17
]}

Yamashita, T. ^{[18
]}

Ikeda, M. ^{[19
]}

Kudo, M. ^{[12
]}

机构：

[1] Osaka Univ, Grad Sch Med, Gastroenterol & Hepatol, Osaka, Japan

[2] Chiba Univ, Sch Med, Gastroenterol, Chiba, Japan

[3] Hiroshima Prefectural Hosp, Gastroenterol, Hiroshima, Japan

[4] Fujita Hlth Univ, Dept Gastroenterol & Hepatol, Toyoake, Aichi, Japan

[5] Ehime Univ, Grad Sch Med, Gastroenterol & Metabol, Matsuyama, Ehime, Japan

[6] Japanese Red Cross Soc Himeji Hosp, Internal Med, Himeji, Hyogo, Japan

[7] Yokohama City Univ, Sch Med, Dept Biostat, Yokohama, Kanagawa, Japan

[8] Jichi Med Univ Hosp, Dept Gastroenterol, Shimotsuke, Tochigi, Japan

[9] Natl Hosp Org Osaka Natl Hosp, Gastroenterol & Hepatol, Osaka, Japan

[10] Toranomon Gen Hosp, Hepatol, Tokyo, Japan

[11] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, Tokyo, Japan

[12] Kindai Univ, Fac Med, Gastroenterol & Hepatol, Osaka, Japan

[13] Ehime Prefectural Cent Hosp, Gastroenterol, Matsuyama, Ehime, Japan

[14] Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, Fukuoka, Japan

[15] NCGM Natl Ctr Global Hlth & Med, Surg, Tokyo, Japan

[16] Kanagawa Canc Ctr, Dept Gastroenterol, Yokohama, Kanagawa, Japan

[17] Kyoto Prefectural Univ Med, Mol Gastroenterol & Hepatol, Kyoto, Japan

[18] Kanazawa Univ Hosp, Gastroenterol Dept, Kanazawa, Ishikawa, Japan

[19] Natl Canc Ctr Hosp East, Hepatobiliary & Pancreat Oncol Dept, Chiba, Japan

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.10.221

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

200P

引用

页码：S1480 / S1481

页数：2

共 50 条

[31] Concurrent transarterial chemoembolization plus atezolizumab and bevacizumab in unresectable hepatocellular carcinoma: Interim analysis from a multicenter real-world study (CHANCE 023).
Zhu, Haidong
Lu, Jian
Teng, Gao-Jun
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 542 - 542
[32] Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Rossari, F.
Tada, T.
Shimose, S.
Kudo, M.
Yoo, C.
Cheon, J.
Finkelmeier, F.
Lim, H. Y.
Presa, J.
Masi, G.
Bergamo, F.
Amadeo, E.
Vitiello, F.
Foti, S.
Persano, M.
Piscaglia, F.
Scartozzi, M.
Cascinu, S.
Rimini, M.
Gardini, A. Casadei
ANNALS OF ONCOLOGY, 2023, 34 : S1547 - S1547
[33] Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study
Rossari, Federico
Tada, Toshifumi
Suda, Goki
Shimose, Shigeo
Kudo, Masatoshi
Yoo, Changhoon
Cheon, Jaekyung
Finkelmeier, Fabian
Lim, Ho Yeong
Presa, Jose
Masi, Gianluca
Bergamo, Francesca
Amadeo, Elisabeth
Vitiello, Francesco
Kumada, Takashi
Sakamoto, Naoya
Iwamoto, Hideki
Aoki, Tomoko
Chon, Hong Jae
Himmelsbach, Vera
Iavarone, Massimo
Cabibbo, Giuseppe
Montes, Margarida
Foschi, Francesco Giuseppe
Vivaldi, Caterina
Solda, Caterina
Sho, Takuya
Niizeki, Takashi
Nishida, Naoshi
Steup, Christoph
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Hatanaka, Takeshi
Kakizaki, Satoru
Shimada, Noritomo
Kawata, Kazuhito
Hiraoka, Atsushi
LIVER CANCER, 2024, 13 (05) : 522 - 536
[34] Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study
Sugimoto, Rie
Satoh, Takeaki
Ueda, Akihiro
Senju, Takeshi
Tanaka, Yuki
Yamashita, Shinsaku
Koyanagi, Toshimasa
Kurashige, Tomoyuki
Higuchi, Nobito
Nakamura, Tsukasa
Tanaka, Masatake
Azuma, Yuuki
Ohno, Akari
Ooho, Aritsune
Ooe, Mari
Mutsuki, Taiji
Uchimura, Koutarou
Kuniyoshi, Masami
Tada, Seiya
Aratake, Yoshifusa
Yoshimoto, Tsuyoshi
Yamashita, Naoki
Harada, Shigeru
Nakamuta, Makoto
Motomura, Kenta
Kohjima, Motoyuki
MEDICINE, 2022, 101 (40) : E30871
[35] Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting
Falette-Puisieux, Manon
Nault, Jean-Charles
Bouattour, Mohamed
Lequoy, Marie
Amaddeo, Giuliana
Decaens, Thomas
Di Fiore, Frederic
Manfredi, Sylvain
Merle, Philippe
Baron, Aurore
Locher, Christophe
Pellat, Anna
Coriat, Romain
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[36] Efficacy and safety in unresectable hepatocellular carcinoma using atezolizumab plus bevacizumab in later-line: A retrospective analysis of real-world evidence.
Cheng, Jiamin
Chen, Bowen
Zhang, Xinfeng
Su, Guodong
Peng, Caiyun
Zhou, Lin
Lei, Jin
Li, Yinyin
Lu, Yinying
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[37] A multicenter, phase 2 study of atezolizumab plus bevacizumab (atezo plus bev) combination therapy in patients with unresectable hepatocellular carcinoma (HCC) and Child-Pugh class B cirrhosis: CHALLENGE trial final results.
Ikeda, Masafumi
Terashima, Takeshi
Yamashita, Tatsuya
Okusaka, Takuji
Imaoka, Hiroshi
Kawaoka, Tomokazu
Kobayashi, Satoshi
Ogasawara, Sadahisa
Hiraoka, Atsushi
Nakano, Masahito
Nagashima, Fumio
Sugimoto, Rie
Moriguchi, Michihisa
Inaba, Yoshitaka
Shinoda, Satoru
Ueno, Makoto
Kato, Naoya
Kudo, Masatoshi
Furuse, Junji
Nagano, Hiroaki
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
[38] EARLY TUMOR RESPONSE AND SAFETY OF ATEZOLIZUMAB PLUS BEVACIZUMAB FOR PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA IN REAL WORLD PRACTICE
Ando, Yuwa
Kawaoka, Tomokazu
Amioka, Kei
Uchikawa, Shinsuke
Kodama, Kenichiro
Fujino, Hatsue
Nakahara, Takashi
Ono, Atsushi
Murakami, Eisuke
Yamauchi, Masami
Imamura, Michio
Aikata, Hiroshi
HEPATOLOGY, 2021, 74 : 636A - 637A
[39] Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in the United States (US): Final analysis of the prospective, observational REFINE study
Kaseb, Ahmed Omar
Cabrera, Roniel
Iyer, Renuka
Parikh, Neehar
Kalman, Richard
Ozgurdal, Kirhan
Khan, Javeed
Babajanyan, Svetlana
Finn, Richard S.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[40] Response prediction model of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: multicenter retrospective study
Ueno, Masaki
Kosaka, Hisashi
Iida, Hiroya
Ida, Yoshiyuki
Aoi, Kazunori
Mori, Haruki
Miyamoto, Atsushi
Nishida, Yuko
Hayami, Shinya
Kawai, Manabu
Kaibori, Masaki
ONCOLOGY, 2023, 101 (09) : 565 - 574

← 1 2 3 4 5 →